Human and mouse PD-L1: similar molecular structure, but different druggability profiles
Katarzyna Magiera‐Mularz(Jagiellonian University), Łukasz Skalniak(Jagiellonian University)
Cited by 106
Related Papers
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
|Oncotarget|2017|308
A PD-1/PD-L1-Sensitive Co-culture-Based Primary T-Cell Activation Assay
|Methods in molecular biology|2025|1
Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model
|Biomedicine & Pharmacotherapy|2025|1